TG Therapeutics TGTX Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermInvestments.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's equity method investments?
- TG Therapeutics (TGTX) reported equity method investments of $61.54M in Q1 2026.
- How has TG Therapeutics's equity method investments changed year-over-year?
- TG Therapeutics's equity method investments increased by 3127.0% year-over-year, from $1.91M to $61.54M.
- What is the long-term trend for TG Therapeutics's equity method investments?
- Over 4 years (2021 to 2025), TG Therapeutics's equity method investments has grown at a 13.6% compound annual growth rate (CAGR), from $35.53M to $59.14M.
- What does equity method investments mean?
- Investments in other companies where the business has significant influence but not full control.
- How do you interpret equity method investments?
- Growth in this balance reflects successful strategic partnerships or the increasing value of collaborative ventures.
- How does equity method investments compare across companies?
- Common in biotech for companies engaged in joint development or co-commercialization agreements.